Brought to you by 
Clovis pays $200mm up front for EOS SPA, gains Phase II breast cancer project
27 Aug 2020
Executive Summary
Clovis Oncology Inc. (cancer therapeutics and companion diagnostics) acquired privately held Italian pharmaceutical company EOS SPA. Clovis paid $200.5mm up front, comprised of $10mm in cash and 3.7mm of its common shares (valued at $190.5mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clovis pays $200mm up front for EOS SPA, gains Phase II breast cancer project
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice